INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 574
COURSE OF VALVE DEFECTS OF RHEUMATIC ETIOLOGY IN PATIENTS WITH
CORONARY HEART DISEASE
Suvonova Aziza Bekzatovna
Independent researcher of Samarkand State Medical University
Abstract:
This article examines the clinical course and interaction between rheumatic valvular
heart disease and coronary heart disease (CHD). The coexistence of these two conditions
presents unique diagnostic and therapeutic challenges, as rheumatic valve lesions may
exacerbate myocardial ischemia, and CHD may complicate the hemodynamic burden of valve
dysfunction. The study highlights pathophysiological mechanisms, clinical manifestations, and
management strategies, emphasizing the need for individualized care in patients presenting with
both conditions. Modern diagnostic tools and surgical interventions have improved outcomes,
yet prognosis largely depends on timely recognition and comprehensive treatment approaches.
Keywords:
Rheumatic heart disease, coronary artery disease, valvular defects, ischemic heart
disease, mitral stenosis, aortic insufficiency, comorbidity, cardiac surgery
Introduction
Rheumatic heart disease (RHD) and coronary heart disease (CHD) are two of the most
prevalent cardiovascular pathologies globally, yet their co-occurrence in the same patient poses
a multifaceted clinical problem. While RHD primarily affects young adults and is the sequela of
acute rheumatic fever, CHD is most commonly observed in older individuals due to
atherosclerosis. However, with increasing life expectancy and improved survival from initial
cardiac events, more patients are being diagnosed with both conditions simultaneously.
Rheumatic valve defects, particularly mitral stenosis and aortic regurgitation, can significantly
alter left ventricular function and intracardiac pressures. In patients with CHD, these alterations
may worsen myocardial perfusion and provoke anginal symptoms even in the absence of
critical coronary stenoses. Conversely, ischemia and ventricular dysfunction from CHD may
unmask or aggravate valvular insufficiency. Understanding the interplay between these
pathologies is critical for accurate diagnosis and optimal management.
Pathophysiology and hemodynamic interaction
Rheumatic valve disease typically results from post-inflammatory fibrosis and
calcification of cardiac valves, most frequently the mitral valve. The narrowing or
incompetence of valves leads to abnormal pressure gradients, volume overload, and progressive
remodeling of cardiac chambers. When superimposed on coronary disease, these changes can
precipitate heart failure symptoms even at rest or with minimal exertion.
For example, mitral stenosis limits diastolic filling, leading to decreased cardiac output. In the
setting of CHD, this reduced perfusion can further compromise coronary flow, especially
during tachycardia or atrial fibrillation, which are common in RHD. Aortic regurgitation causes
left ventricular volume overload, which, if accompanied by ischemia, can rapidly decompensate
into left-sided heart failure.
Clinical presentation
Patients with concurrent RHD and CHD often present with overlapping symptoms:
exertional dyspnea, chest pain, palpitations, and fatigue. However, the clinical picture may be
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 575
misleading. Anginal chest pain may be due to reduced coronary reserve from valvular
abnormalities rather than obstructive coronary disease alone. Likewise, symptoms traditionally
attributed to CHD may in fact stem from progressive valvular deterioration.
Electrocardiography may reveal left atrial enlargement or left ventricular hypertrophy in
valvular disease, while ischemic changes may signal active coronary involvement.
Echocardiography remains central to assessing valve structure and function, while coronary
angiography is essential before any surgical intervention.
Diagnosis and risk stratification
Modern imaging techniques such as transesophageal echocardiography, cardiac MRI,
and CT coronary angiography enable detailed evaluation of both valvular and coronary
anatomy. Risk stratification involves not only estimating surgical risk but also evaluating
myocardial viability, presence of arrhythmias, and degree of functional impairment.
In patients undergoing valve surgery, it is essential to assess coronary arteries preoperatively, as
silent CHD may worsen postoperative outcomes. Combined valve replacement and coronary
artery bypass grafting (CABG) are often required, especially in elderly patients or those with
multivessel disease.
Management strategies
Management of patients with dual pathology is highly individualized and depends on the
dominant clinical picture. Medical treatment includes optimization of heart failure therapy, rate
or rhythm control in atrial fibrillation, and use of antiplatelet agents and statins in patients with
ischemia.
Surgical intervention, including valve repair or replacement with or without CABG, remains the
mainstay for patients with significant symptomatic valvular disease and coexisting CHD.
Percutaneous interventions such as balloon valvuloplasty or transcatheter aortic valve
replacement (TAVR) may be considered in selected high-risk patients.
Long-term follow-up is crucial to monitor prosthetic valve function, progression of coronary
disease, and control of risk factors such as hypertension, diabetes, and dyslipidemia.
Pathophysiology and hemodynamic interactions
Rheumatic heart disease (RHD) arises from autoimmune reactions following untreated
or inadequately treated group A streptococcal pharyngitis. These immune responses primarily
target the cardiac valves, leading to progressive fibrosis, leaflet thickening, commissural fusion,
and eventually valvular stenosis or regurgitation. The mitral valve is most commonly affected,
followed by the aortic valve. In the context of coronary heart disease (CHD), the hemodynamic
burden imposed by valvular abnormalities can significantly worsen myocardial ischemia and
contribute to rapid decompensation.
When a patient has both CHD and RHD, a "vicious cycle" often forms: impaired valve function
causes volume or pressure overload in the heart chambers, which increases myocardial oxygen
demand. If coronary perfusion is already compromised due to atherosclerotic lesions, this added
stress can trigger angina, arrhythmias, or even myocardial infarction. For example, in a patient
with mitral stenosis, elevated left atrial pressures may lead to pulmonary hypertension and right
heart failure, while reduced preload impairs cardiac output, aggravating ischemia in coronary-
prone territories.
Types of valve lesions and their impact in CHD
Mitral stenosis (MS):
Commonly caused by RHD, MS restricts blood flow from the
left atrium to the left ventricle, reducing preload and thereby limiting cardiac output. In
CHD patients, this exacerbates exercise intolerance and ischemia. Moreover, the
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 576
stagnant blood flow in the left atrium increases the risk of thrombus formation,
especially in patients with atrial fibrillation.
Aortic regurgitation (AR):
This lesion causes volume overload of the left ventricle,
increasing wall stress and oxygen demand. In patients with compromised coronary
arteries, the ventricle struggles to adapt, leading to early heart failure symptoms.
Diastolic pressure drops due to regurgitation may further impair coronary perfusion, as
coronary arteries fill during diastole.
Mixed lesions:
Many rheumatic patients present with combinations such as mitral
stenosis and regurgitation, or both mitral and aortic valve involvement. These complex
lesions further complicate the clinical picture in CHD, requiring a nuanced therapeutic
approach.
Clinical manifestations and diagnostic challenges
Symptoms often overlap between the two diseases and may mask each other. For example,
shortness of breath and fatigue may result from left-sided heart failure due to CHD, or from
pulmonary congestion caused by mitral stenosis. Anginal pain might be a true ischemic event,
or secondary to increased left ventricular wall stress in the presence of aortic insufficiency.
A detailed clinical assessment, including auscultation, may reveal murmurs suggesting valve
pathology; however, physical signs are not always reliable. Many elderly patients with CHD
have calcified valves, and distinguishing degenerative changes from rheumatic pathology can
be difficult without imaging.
Echocardiography
(especially transesophageal) remains the gold standard for
evaluating valve morphology and function.
Cardiac catheterization and coronary angiography
are crucial before planning
surgery, especially for patients above 40 or with angina symptoms.
Stress testing, CT angiography
, and
MRI
help in assessing myocardial viability and
coronary perfusion, particularly when noninvasive functional data is needed.
Surgical Considerations and Interventional Approaches
Surgical intervention in patients with both CHD and rheumatic valve disease must be
individualized. The decision to perform valve surgery alone, coronary artery bypass grafting
(CABG), or a combined procedure depends on the severity of each condition and the patient’s
functional status.
Combined Valve Surgery + CABG
is recommended for patients with significant valve
lesions and angiographically confirmed multi-vessel or left main disease.
Valve Replacement or Repair
may be performed with minimally invasive techniques,
especially in younger rheumatic patients with isolated valve disease but incidental
coronary stenosis.
Percutaneous interventions
like
balloon mitral valvotomy
are often used for isolated
mitral stenosis with favorable valve anatomy, even in the presence of mild CHD.
For high-risk surgical candidates, Transcatheter Aortic Valve Replacement (TAVR) has
shown promising results and is increasingly used in elderly patients with comorbidities.
Postoperative outcomes depend heavily on the completeness of revascularization, the
preservation of ventricular function, and rhythm control (especially if atrial fibrillation is
present). Long-term anticoagulation is often needed in valve replacement patients, which must
be carefully managed to avoid ischemic or hemorrhagic complications, especially when
concomitant CHD warrants antiplatelet therapy.
Prognostic implications and long-term management
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 577
The prognosis of patients with both RHD and CHD is generally worse than those with either
condition alone. Key predictors of poor outcome include:
Reduced ejection fraction
Severe pulmonary hypertension
Left main or triple-vessel coronary disease
Persistent atrial fibrillation
Delayed surgical intervention
Conclusion
The coexistence of rheumatic valve disease and coronary heart disease requires a
multidisciplinary approach that considers the hemodynamic and clinical interactions between
the two conditions. Early recognition and timely intervention are key to improving prognosis.
Advances in diagnostic imaging, surgical techniques, and postoperative care have significantly
enhanced outcomes, yet the complexity of these cases demands tailored treatment plans based
on individual risk profiles and disease burden.
References:
1.
Otto, C. M., & Nishimura, R. A. (2020). Valvular Heart Disease: A Companion to
Braunwald’s Heart Disease. Elsevier.
2.
Carapetis, J. R., Beaton, A., & Zühlke, L. J. (2019). Global burden of rheumatic heart
disease. New England Journal of Medicine, 377(8), 713–722.
3.
Nishimura, R. A., et al. (2020). 2020 ACC/AHA Guideline for the Management of Patients
with Valvular Heart Disease. Journal of the American College of Cardiology.
4.
Yusuf, S., Hawken, S., & Ounpuu, S. (2022). Effect of potentially modifiable risk factors
associated with myocardial infarction. The Lancet.
5.
Unger, E., & Escobar, E. (2021). Valvular heart disease and ischemic heart disease:
interplay and surgical considerations. European Journal of Cardiothoracic Surgery, 59(4),
802–810.
